David H. Henry, MD, and Ruben A. Mesa, MD, on Myelofibrosis: Trial Results From a Best of ASCO Abstract
2017 ASCO Annual MeetingDavid H. Henry, MD, of Pennsylvania Oncology Hematology Associates, and Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discuss phase III study findings on momelotinib vs ruxolitinib in JAK inhibitor–naive patients with myelofibrosis. (Abstract 7000)
Related Videos
Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial
Karim Fizazi, MD, PhD, of the University Paris-Sud, discusses study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed...
Elizabeth R. Plimack, MD, on Advanced Urothelial Cancer: Expert Perspective
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annu...
Elizabeth J. Shpall, MD, and Nina Shah, MD—Mentor and Mentee: A Conversation
Elizabeth J. Shpall, MD, of The University of Texas MD Anderson Cancer Center, and recipient of the 2017 Women Who Conquer Cancer Mentorship Award, discusses promoting women in onc...
Ethan M. Basch, MD, on Symptom Monitoring: Findings on Overall Survival Rates
Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatme...
Solange Peters, MD, PhD, and Mary Gospodarowicz, MD, on Mentoring Women in Oncology: An International Perspective
Solange Peters, MD, PhD, of the University of Lausanne, who has been a driving force in ESMO’s efforts to promote women in oncology, talks with Mary Gospodarowicz, MD
